Paper · 42964697
Endocrine resistance in HR+/HER2- breast cancer: molecular mechanisms and emerging therapeutic strategies.
Shen T and 3 others. Front Oncol, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Endocrine resistance in HR+/HER2- breast cancer: molecular mechanisms and emerging therapeutic strategies. Papers, record 42964697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42964697
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Endocrine resistance in HR+/HER2- breast cancer: molecular mechanisms and emerging therapeutic strategies.
- Journal
- Front Oncol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-11-02
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References94
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39,660,834 | Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. | N Engl J Med | 2025 | https://conductscience.org/library/papers/39660834 | PubMed |
| 2 | 38,885,540 | Long road towards effective HER3 targeting in breast cancer. | Cancer Treat Rev | 2024 | https://conductscience.org/library/papers/38885540 | PubMed |
| 3 | 39,265,124 | Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/39265124 | PubMed |
| 4 | 34,392,831 | ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. | Breast Cancer Res | 2021 | https://conductscience.org/library/papers/34392831 | PubMed |
| 5 | 36,153,348 | Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. | NPJ Precis Oncol | 2022 | https://conductscience.org/library/papers/36153348 | PubMed |
| 6 | 34,544,753 | RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34544753 | PubMed |
| 7 | 37,801,505 | LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein. | Sci Adv | 2023 | https://conductscience.org/library/papers/37801505 | PubMed |
| 8 | 30,537,512 | Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. | Cancer Cell | 2018 | https://conductscience.org/library/papers/30537512 | PubMed |
| 9 | 40,864,501 | FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40864501 | PubMed |
| 10 | 37,047,814 | A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047814 | PubMed |
1 to 10 of 94
See all 94 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42964697
GET https://conductscience.org/api/papers/v1/42964697/references?page=2